Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Mepolizumab and exacerbations of refractory eosinophilic asthma.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.

N Engl J Med. 2009 Mar 5;360(10):973-84. doi: 10.1056/NEJMoa0808991. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

2.

Mepolizumab versus placebo for asthma.

Powell C, Milan SJ, Dwan K, Bax L, Walters N.

Cochrane Database Syst Rev. 2015 Jul 27;(7):CD010834. doi: 10.1002/14651858.CD010834.pub2. Review.

PMID:
26214266
3.

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.

Hilvering B, Xue L, Pavord ID.

Ther Adv Respir Dis. 2015 Aug;9(4):135-45. doi: 10.1177/1753465815581279. Review.

PMID:
25900924
5.

Mepolizumab and eosinophil-mediated disease.

Walsh GM.

Curr Med Chem. 2009;16(36):4774-8. Review.

PMID:
19929788
6.

Mepolizumab: First Global Approval.

Keating GM.

Drugs. 2015 Dec;75(18):2163-9. doi: 10.1007/s40265-015-0513-8. Review.

PMID:
26603873
7.

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.

Smith DA, Minthorn EA, Beerahee M.

Clin Pharmacokinet. 2011 Apr;50(4):215-27. doi: 10.2165/11584340-000000000-00000. Review.

PMID:
21348536
8.

Mepolizumab: A Review in Eosinophilic Asthma.

Deeks ED.

BioDrugs. 2016 Aug;30(4):361-70. doi: 10.1007/s40259-016-0182-5. Review.

PMID:
27311938
9.

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma.

Anderson DE, Kew KM, Boyter AC.

Cochrane Database Syst Rev. 2015 Aug 24;(8):CD011397. doi: 10.1002/14651858.CD011397.pub2. Review.

PMID:
26301488
10.

Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.

Kew KM, Karner C, Mindus SM, Ferrara G.

Cochrane Database Syst Rev. 2013 Dec 16;(12):CD009019. doi: 10.1002/14651858.CD009019.pub2. Review.

PMID:
24343671
11.

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma.

Kew KM, Evans DJ, Allison DE, Boyter AC.

Cochrane Database Syst Rev. 2015 Jun 2;(6):CD011438. doi: 10.1002/14651858.CD011438.pub2. Review.

PMID:
26031392
12.

A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.

Busse WW, Ring J, Huss-Marp J, Kahn JE.

J Allergy Clin Immunol. 2010 Apr;125(4):803-13. doi: 10.1016/j.jaci.2009.11.048. Review.

PMID:
20371394
13.

Mepolizumab-based therapy in asthma: an update.

Walsh GM.

Curr Opin Allergy Clin Immunol. 2015 Aug;15(4):392-6. doi: 10.1097/ACI.0000000000000183. Review.

PMID:
26110690
14.

Mepolizumab in the treatment of severe eosinophilic asthma.

Fainardi V, Pisi G, Chetta A.

Immunotherapy. 2016;8(1):27-34. doi: 10.2217/imt.15.102. Review.

PMID:
26653083
15.

Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.

Kew KM, Dahri K.

Cochrane Database Syst Rev. 2016 Jan 21;(1):CD011721. doi: 10.1002/14651858.CD011721.pub2. Review.

PMID:
26798035
16.

Mepolizumab for eosinophilic severe asthma: recent studies.

Robinson DS, Kariyawasam HH.

Expert Opin Biol Ther. 2015 Jun;15(6):909-14. doi: 10.1517/14712598.2015.1041911. Review.

PMID:
25951938
17.

The safety of mepolizumab for the treatment of asthma.

Leung E, Al Efraij K, FitzGerald JM.

Expert Opin Drug Saf. 2017 Mar;16(3):397-404. doi: 10.1080/14740338.2017.1286327. Review.

PMID:
28116937
18.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
19.

Omalizumab for asthma in adults and children.

Normansell R, Walker S, Milan SJ, Walters EH, Nair P.

Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559. doi: 10.1002/14651858.CD003559.pub4. Review.

PMID:
24414989
20.

Monoclonal antibodies for the treatment of refractory asthma.

Hambly N, Nair P.

Curr Opin Pulm Med. 2014 Jan;20(1):87-94. doi: 10.1097/MCP.0000000000000007. Review.

PMID:
24275927

Supplemental Content

Support Center